The sellside sees the Duchenne muscular dystrophy market as pretty much sewn up by Sarepta Therapeutics, Inc.. That group had the top three products on the market last year, and its new gene therapy, Elevidys (delandistrogene moxeparvovec), has 2028 sales forecasts of more than $3bn, Evaluate Pharma data show.
Key Takeaways
- ITF Therapeutics’ Duchenne muscular dystrophy therapy Duvyzat has been given a broad label
- But Sarepta dominates the space, with expectations for its gene therapy Elevidys particularly high ...
Last week, though, a new player entered the game: Italfarmaco S.p.A., via its purpose-built US subsidiary, ITF Therapeutics. On 22 March, the US Food and Drug Administration approved ITF’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
